🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to scientists.

A Worldwide Challenge

Gonorrhoea infections are escalating worldwide, with estimates suggesting in excess of 82 million instances per year. Notably increased rates are seen in Africa and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a historical peak, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an important and timely step in the face of increasing worldwide cases, the spread of superbugs and the very limited treatment choices at this time.”

Medical experts are increasingly worried about the rise in antibiotic-resistant strains. The World Health Organization has designated it as a "priority pathogen". Recent surveillance showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Treatment Options Receive Clearance

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists believe that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This treatment, which is additionally indicated for urinary tract infections, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This milestone marks a huge turning point in the treatment of superbug gonorrhoea, which until now has been outpacing antibiotic development.”

Clinical Trial Results and Global Access

As per findings detailed in a prominent scientific publication, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This establishes an comparable level with the typical regimen, which uses two antibiotics. The trial included over 900 patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the ability to register and commercialise the drug in many developing nations.

Doctors on the front lines have voiced optimism. The availability of a easy-to-administer therapy like this is seen as a "critical tool" for managing the epidemic. This is viewed as crucial to alleviate the strain of the infection for individuals and to prevent the spread of untreatable gonorrhoea globally.